Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis

Gang, Pan Jian; Liu, Mo; Yang, Lu; Luo, Rong; Zhou, Xing

doi:10.3109/07435800.2014.934961

Cited by 64 publications

(24 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher plasma phosphatidylcholine concentrations in patients with prostate cancer than in controls have been reported [31], which is in line with the positive association of PC ae C30:0 with risk. While possible mechanisms for the inverse associations between several phosphatidylcholines and advanced prostate cancer are not clear, positive associations have been reported between concentrations of diacyl-phosphatidylcholines (denoted PC aa Cx:y in the current paper) and type 2 diabetes [34], which is linked to a lower prostate cancer risk [35, 36]. The association between phosphatidylcholines and risk might apply to malignancies in general rather than being prostate cancer specific.…”

Section: Discussionmentioning

confidence: 75%

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition

Schmidt

Fensom

Rinaldi

et al. 2017

BMC Med

View full text Add to dashboard Cite

BackgroundLittle is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer.MethodsIn a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure.ResultsSeven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p < 0.05), but none of the associations were statistically significant after controlling for multiple testing. Citrulline was associated with a decreased risk of prostate cancer (odds ratio (OR1SD) = 0.73; 95% confidence interval (CI) 0.62–0.86; p trend = 0.0002) in the first 5 years of follow-up after taking multiple testing into account, but not after longer follow-up; results for other metabolites did not vary by time to diagnosis. After controlling for multiple testing, 12 glycerophospholipids were inversely associated with advanced stage disease, with risk reduction up to 46% per standard deviation increase in concentration (OR1SD = 0.54; 95% CI 0.40–0.72; p trend = 0.00004 for PC aa C40:3). Death from prostate cancer was associated with higher concentrations of acylcarnitine C3, amino acids methionine and trans-4-hydroxyproline, biogenic amine ADMA, hexose and sphingolipid SM (OH) C14:1 and lower concentration of glycerophospholipid PC aa C42:4.ConclusionsSeveral metabolites, i.e. C18:1, citrulline, trans-4-hydroxyproline, three glycerophospholipids and SM (OH) C14:1, might be related to prostate cancer. Analyses by time to diagnosis indicated that citrulline may be a marker of subclinical prostate cancer, while other metabolites might be related to aetiology. Several glycerophospholipids were inversely related to advanced stage disease. More prospective data are needed to confirm these associations.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-017-0885-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 75%

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition

Schmidt

Fensom

Rinaldi

et al. 2017

BMC Med

View full text Add to dashboard Cite

show abstract

“…Significant differences according to race in the association between diabetes and the development of prostate cancer have been seen in other studies 22. One study was carried out with a Western population and provided evidence of an inverse association between diabetes and prostate cancer 18, 23.…”

Section: Discussionmentioning

confidence: 85%

The Impact of Diabetes on the Risk of Prostate Cancer Development according to Body Mass Index: A 10-year Nationwide Cohort Study

et al. 2016

View full text Add to dashboard Cite

Purpose: We examined the association between obesity and prostate cancer both with and without diabetic patients included in the analysis using nationally representative data of the Korean population from the National Health Insurance System (NHIS).Materials and Methods: Of the 424,712 participants who underwent health examinations in 2002-2008, 139,519 men ≥40 years old and without prostate cancer were followed from the beginning of 2002 to the end of 2012. Multivariate adjusted Cox regression analysis was conducted to examine the hazard ratio (HR) and 95% confidence interval (CI) for the association between prostate cancer and body mass index (BMI) both with and without diabetes.Results: The HR for prostate cancer according to the existence of diabetes was stratified by BMI in both age- and multivariable-adjusted models. In the population without diabetes, the HR for prostate cancer significantly increased as BMI increased beyond the reference range in a model adjusted for age and multiple variables; however, the increase in the HR was small. In the population with diabetes, the HR for prostate cancer significantly increased as BMI increased from < 18.5 kg/m2 to within the reference range (18.5 to 22.9) in the multivariable-adjusted model. In addition, a marked decrease in HR in the population with BMI of < 18.5 kg/m2 was seen compared to the reference or higher BMI population.Conclusion: This population-based study shows the evidence of association between obesity and development of prostate cancer, and the risk increases vary according to the change of BMI category and the existence of diabetes.

show abstract

“…[ 1 ] The established causal risk factors for bladder cancer include gender, age, smoking, early menopause, and occupational exposure. [ 2 – 6 ] Diabetes mellitus (DM) is associated with elevated risks of cancer at different sites, including biliary tract, [ 7 ] lung, [ 8 ] hepatocellular, [ 9 ] colorectal, [ 10 ] ovarian, [ 11 ] prostate, [ 12 ] breast, [ 13 ] renal, [ 14 ] esophageal, [ 15 ] gastric, [ 16 ] non-Hodgkin lymphoma, leukemia, and myeloma, [ 17 ] pancreatic, [ 18 ] and endometrial [ 19 ] cancers. Further, although numerous meta-analyses have evaluated the association of DM with the risk of bladder cancer, [ 20 – 25 ] inconsistent results have been reported and require further verification.…”

Section: Introductionmentioning

confidence: 99%

Diabetes mellitus and the risk of bladder cancer

Huo

Chen

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis

Abstract: Further research should focus on limitations in the current literature and re-assess the relationship between diabetes and prostate cancer by analyzing the two different diabetes mellitus types separately.

Cited by 64 publications

References 67 publications

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition

The Impact of Diabetes on the Risk of Prostate Cancer Development according to Body Mass Index: A 10-year Nationwide Cohort Study

Diabetes mellitus and the risk of bladder cancer

Contact Info

Product

Resources

About